Areas of Interest

Enlight Biosciences is focused on developing transformational enabling technologies in areas of highest potential impact within the drug discovery process, with an emphasis on technologies that strengthen the connection between preclinical research, clinical research, and point-of-care.

 

Areas of interest include technologies that increase the ultimate likelihood of success of drugs that pass early development milestones (e.g., drug discovery, chemistry and synthesis platforms); technologies for early prediction of human response (e.g., predictive efficacy models, predictors of pharmacokinetics and toxicology); technologies that provide accurate readouts of both animal and human response to intervention (e.g., molecular imaging and biomarkers); and technologies to make promising chemical and biological compounds better suited to human treatment (e.g., formulation and drug delivery technologies). Examples of specific technology interest areas within these categories are outlined below:

  
     

Imaging/biomarkers

  • Novel high contrast, high resolution imaging modalities suitable to clinical translation
  • Novel targeted smart probes for molecular imaging of as yet intractable metabolic, central nervous system, oncologic, inflammatory and cardiovascular diseases
  

Safety/toxicology

  • Early predictors of human ADME/tox
  • In vitro tissue-mimicking toxicology assays

Predictive Models

  • Novel models of disease which are truly predictive of human molecular processes and disease pathologies
  • Computational models of clinical trial response
  

Chemistry/biochemistry

  • Broadly applicable chemistry platforms/scaffolds

Synthesis/production

  • Protein expression automation, production cell lines
  • Dramatically faster compound synthesis
  

Biomarkers

  • Systems biology/multi-marker patterns, protein/antibody arrays
  • Label-free binding assay methods
  • Platforms for patient segmentation

Formulation/delivery

  • Non-parenteral methods of protein or siRNA delivery
  • Technologies for delivery across the blood-brain barrier
  • Tissue targeted delivery technologies
  • Platforms for combination therapies
  

Biologic Platforms

  • Engineered antibody alternatives with superior properties
  • Novel antibody discovery platforms
  • Novel protein expression platforms
  • Technologies to improve stability, half-life, cell permeability, and tissue targeting